FDA Clarifies Leucovorin Is Not Approved for Autism Treatment Amid Off-Label Use

The U.S. Food and Drug Administration (FDA) recently clarified that leucovorin, a medication used to treat folate deficiency disorders, is not approved for autism spectrum disorder (ASD) treatment. This statement, reported by CNN in March 2026, comes amid increasing unapproved use of the drug by some families and clinicians exploring options for autism-related support needs.

Understanding Leucovorin's Role

Leucovorin (also known as folinic acid) has been discussed by some advocacy groups and researchers as a potential support for autism, particularly for individuals with folate-related metabolic differences. However, the FDA emphasized that its approval is strictly limited to specific folate deficiency conditions, not ASD. While individual reports suggest benefits for some autistic individuals, no large-scale clinical trials have confirmed its efficacy for core aspects of autism, as noted in systematic reviews of autism drug development.

These suggest possible pathways that could influence autism-related biology, but human trials remain limited.

Current Medication Options

At present, only two medications—risperidone and aripiprazole—are FDA-approved for autism-related support, and these target only associated irritability and aggression, not core differences in social communication. A 2026 Frontiers review highlights how genetic variations might influence individual responses to risperidone, showing the complexity of finding pharmacological supports for autism.

Research Directions

Early-stage studies, including recent animal model research published in Nature, have explored drugs like suramin (an antiparasitic) and repurposed epilepsy medications. These suggest possible pathways that could influence autism-related biology, but human trials remain limited. One ongoing study, listed on CenterWatch, is testing suramin in autistic children, though results are not yet available.

Navigating Support Options

Decades of research have yet to yield pharmacological treatments with strong evidence for autism's core aspects, as reiterated in peer-reviewed systematic reviews. Many families combine behavioral therapies, educational supports, and—in some cases—unapproved medications with careful consideration of risks and benefits.